Release Date: 16-Jul-2024
In the realm of cancer immunology, Exlinkibart has emerged as a promised contender, serving as a next-generation agonistic monoclonal antibody against CD137. The focus on CD137, a co-stimulatory receptor on T cells, underscores a strategic approach to leveraging the immune system against cancer cells and unlocking novel therapeutic possibilities for various cancers. Exlinkibart was developed by Lyvgen Biopharma, a Shanghai-based biopharmaceutical company.
CD137, also known as 4-1BB, is a crucial co-stimulatory receptor expressed by activating immune cells, particularly T cells. Its role in cancer is pivotal, as its activation promotes the expansion and functionality of T cells, contributing to an enhanced anti-tumor response. Harnessing the power of CD137 has emerged as a promising strategy in cancer immunotherapy due to its potential to bolster the immune system’s ability to recognize and eliminate cancer cells.
Exlinkibart works as an agonistic monoclonal antibody, which means it promotes CD137 activity. It targets and binds to CD137 after delivery, activating CD137 expression on a range of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This increases CD137-mediated signaling, boosts cytotoxic T-lymphocyte (CTL) proliferation, cytokine generation, and enhances a CTL-mediated anti-tumor immune response, as well as induces NK-mediated tumor cell killing and reduces T-regulatory cell (Treg) immunosuppressive activity. This prepares the immune system to launch a powerful and targeted attack on cancer cells, bolstering the body’s natural defenses.
Exlinkibart’s journey through rigorous clinical trials provides a look into its potential as a medicinal agent. In addition to normal chemotherapy, Lyvgen is testing Exlinkibart alone or in combination with the anti-PD-1 antibody Pembrolizumab and the VEGFR tyrosine kinase Anlotinib in adult patients with advanced cancer. In late-stage cancer patients, preliminary anticancer activity was seen. According to early clinical trial results, the combination with pembrolizumab generated rapid antitumor responses in advanced cancer patients with immune-cold tumors or who had relapsed from past immunotherapies.
In conclusion, Exlinkibart shows great promise for the future of solid cancer treatment. Its capacity to stimulate the immune system via CD137 targeting places it at the forefront of precision medicine development, opening up new pathways for personalizing therapy to particular patients and cancer types. Exlinkibart, as a next-generation CD137 agonistic antibody, has the potential to become a cornerstone in the treatment of a variety of cancers if continuing clinical trials show positive results.
For Clinical Trials Information Contact